John is the Lead Equity Analyst for Stansberry Innovations Report, a monthly research advisory that shows subscribers how to invest safely in the next technology revolutions. He and the Innovations team look for strong companies that are staking out their spots in the burgeoning technology industry, treating shareholders right, and providing the opportunity for outstanding gains.
John holds a Master of Science from Johns Hopkins University and has real world experience working at both a biotech startup and large pharmaceutical company. Prior to joining Stansberry Research, John worked as a research scientist in a drug discovery lab, where he spent years developing novel therapeutics.
He is also a research analyst for Stansberry Venture Technology – our premium advisory service focused on emerging technologies and biotechnologies. And he is lead analyst and collaborating contributor to Doc Eifrig’s health care newsletter, Prosperity Investor.
John is a valuable asset to our team as we hunt for and analyze new scientific breakthroughs.
John’s Latest Content
A Rush for the Exits Has Begun
Volatility reigns... The week Greg Diamond says stocks will top... The latest about Iran and oil... Rushing for the exits...
Read the article
Protect Yourself From the Oncoming 'Fever'
Pollen season is longer than ever in the U.S...
Read the article
Why I think the Iran war will end soon; Bill Ackman is taking Pershing Square public; Update on Joby Aviation; No success on the courts, but I had a blast
1) I wrote yesterday that investors should "ignore the headlines and stay the course." One reason is that I think...
Read the article
Now's Not the Time to Argue With the Market
You can find plenty of reasons to worry about the future right now. But the market isn't panicking – and...
Read the article